Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca falls to five-month low on breast cancer trial results
07:16am, Monday, 23'rd Sep 2024
AstraZeneca PLC (LSE:AZN) shares fell to a five-month low after it confirmed that another failed cancer trial of its Dato-DXd drug. The largest company in the FTSE 100 said it will continue to talk to
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
02:26am, Monday, 23'rd Sep 2024
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline results from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) compared to investigator's choice of chemotherapy, which prev
Astrazeneca (AZN) Suffers a Larger Drop Than the General Market: Key Insights
07:21pm, Friday, 20'th Sep 2024
The latest trading day saw Astrazeneca (AZN) settling at $78.38, representing a -0.66% change from its previous close.
US FDA approves AstraZeneca's flu vaccine for self-administration
12:22pm, Friday, 20'th Sep 2024
The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's influenza nasal spray vaccine for self-administration, making it the first of its kind that patients can give themsel
Wall Street Bulls Look Optimistic About Astrazeneca (AZN): Should You Buy?
10:36am, Thursday, 19'th Sep 2024
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often
2 Unstoppable S&P 500 Dividend Stocks to Buy Before They Beat the Market Again
04:21am, Thursday, 19'th Sep 2024
AstraZeneca and AbbVie outperformed the benchmark S&P 500 index over the past three-year, five-year, and 10-year periods. AbbVie offers a relatively high yield due to declining sales of its former lea
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease
12:16pm, Wednesday, 18'th Sep 2024
The FDA okays AstraZeneca's Fasenra for treating adults with eosinophilic granulomatosis with polyangiitis. This is the second approved indication for the drug.
AstraZeneca PLC (AZN) Meet the Management at ESMO 2024 Conference (Transcript)
06:43pm, Tuesday, 17'th Sep 2024
AstraZeneca PLC (NASDAQ:AZN ) Meet the Management at ESMO 2024 Conference September 16, 2024 2:00 PM ET Company Participants Pascal Soriot - Chief Executive Officer Susan Galbraith - EVP, Oncology R&D
5 Oversold Stocks to Buy Right Now
11:27am, Monday, 16'th Sep 2024
Investors like to think of themselves as rational and unattached. Still, the movement of stock prices shows that this isn't always true — and the existence of technical signals like oversold or unde
Radioactive cancer technology: New billion dollar opportunity?
09:33am, Monday, 16'th Sep 2024
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news.
AstraZeneca Stock Downgraded on Drug Trial Results
09:20am, Friday, 13'th Sep 2024
Biopharmaceutical stock AstraZeneca PLC (NASDAQ:AZN) is 1.3% lower before the open, after a bear note from Deutsche Bank.
Moffitt Cancer Center Announces Strategic Collaboration with AstraZeneca to Accelerate Oncology Cell Therapies
09:00am, Friday, 13'th Sep 2024
TAMPA, Fla.--(BUSINESS WIRE)--Moffitt Cancer Center announces today a strategic collaboration with AstraZeneca that aims to accelerate the development of cell therapies, specifically chimeric antigen
AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
08:00am, Thursday, 12'th Sep 2024
AstraZeneca's Dato-DXd showed disappointing overall survival data in the TROPION-Lung01 phase 3 trial. Dato-DXd's progression-free survival benefit, especially in biomarker-positive patients, and the
First patient enrolled in Phase 2a study arm combining BI-1206 with rituximab and acalabrutinibwith initial data expected YE 2024 Clinical supply agreement for acalabrutinib with AstraZeneca in place
